Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
TRDA

TRDA - Entrada Therapeutics, Inc. Stock Price, Fair Value and News

$6.44+0.13 (+2.06%)
Market Closed as of 12 Jun 2026, 04:00 pm ET

57/100

TRDA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

57/100

TRDA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

TRDA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TRDA Price Action

Last 7 days

1.1%

Last 30 days

-12.0%

Last 90 days

-49.2%

Trailing 12 Months

-18.0%

TRDA RSI Chart

TRDA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TRDA Valuation

Market Cap

250.0M

Price/Earnings (Trailing)

-1.5

Price/Sales (Trailing)

9.83

Price/Free Cashflow

-1.9

TRDA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

TRDA Fundamentals

TRDA Revenue

Rev. Growth (Yr)

-96.53%

Rev. Growth (Qtr)

-19.52%

TRDA Earnings

Earnings (TTM)

-166.1M

Earnings Growth (Yr)

-128.93%

Earnings Growth (Qtr)

-1.41%

TRDA Profitability

Return on Equity

-61.33%

Return on Assets

-49.51%

Free Cashflow Yield

-52.66%

TRDA Investor Care

Shares Dilution (1Y)

2.31%

Diluted EPS (TTM)

-3.99

TRDA Alerts

  • 1 major insider buys recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20260000
2025172.2M79.5M61.5M25.4M
2024162.9M239.4M215.2M210.8M
202327.4M45.2M88.1M129.0M
2022714.8K905.0K1.7M2.6M
2021334.3K524.5K00
2020000144.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Entrada Therapeutics, Inc.

TRDA
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead therapeutic candidates, which include ENTR-601-44 and ENTR-601-45, which are in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1; ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy; and ENTR-701, which is in preclinical trail for the treatment of myotonic dystrophy type 1. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEentradatx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES131

Entrada Therapeutics, Inc. Frequently Asked Questions

TRDA is the stock ticker symbol of Entrada Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jun 12 2026, market cap of Entrada Therapeutics, Inc. is 250 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jun 12 2026, TRDA's PE ratio (Price to Earnings) is -1.5 and Price to Sales (PS) ratio is 9.83. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TRDA PE ratio will change depending on the future growth rate expectations of investors.